ABSTRACT
Oocyte donation represents an exceptional situation in assisted reproduction technologies (ART), since the oocytes are derived from young fertile women, and the resulting embryos are transferred to the uterus of a different woman who has been previously prepared with a controlled regimen of exogenous estrogen and progesterone optimizing the endometrial receptivity. This model in turn makes possible the optimization of oocyte quality and therefore embryo quality, since oocytes are recruited from young healthy women. This fact has contributed to increase the number of indications for this therapeutic option in infertile patients, initially intended for young women with premature ovarian failure (POF) (1). As a result, this strategy is nowadays a well-established practice, currently applied in cases of heritable maternal genetic disorders (2), early perimenopausal and/or menopausal women (3), poor responder patients (4), or in cases of multiple unsuccessful in vitro fertilization (IVF) attempts (5).
